FB Live Q&A 02 07 2026 скачать в хорошем качестве

FB Live Q&A 02 07 2026

Summary of LDN Support Group Live Q&A Session Dr. Yoon-Hang Kim hosted his regular Saturday morning live Q&A session for the LDN Support Group, running approximately 55 minutes due to high engagement, with more than 30 real-time questions and comments. Throughout the session, Dr. Kim emphasized education and shared clinical experience while intentionally avoiding individualized medical advice, consistently modeling Facebook-compliant language. The dominant theme of the session was Dr. Kim’s dosing philosophy for low-dose naltrexone (LDN), summarized as “start low and go slow.” He stressed that LDN dosing must be individualized based on patient complexity and immune sensitivity. In his practice, a typical starting dose is 0.1 mg (100 mcg), though some patients begin as low as 1 mcg. He defined ultra-low dose LDN as 1–10 mcg and clarified that doses such as 0.5 mg should not be considered “low” in sensitive patients. He outlined a tiered approach: patients with a single concern may start at 0.1 mg, those with two concerns at 0.01 mg, and patients with multiple conditions or suspected MCAS at 1 mcg. Titration should only occur when there are neither side effects nor desired clinical effects. For neuropathic pain, he noted that higher doses, including 4–9 mg and even twice-daily dosing, may be appropriate. As a personal example, he shared that he initially started at 6 mg for nerve pain and experienced transient side effects before tolerating the dose. Mast Cell Activation Syndrome (MCAS) was discussed extensively as a core concept in Dr. Kim’s root-cause framework. He described MCAS not as a discrete diagnosis but as a state of immune dysregulation, using the analogy of a “kidnapper” bringing the body into “the land of MCAS.” Common triggers he identified included Lyme disease, mold exposure, post-COVID syndromes, antibiotic use, and surgery. He emphasized a “siege, not frontal assault” treatment philosophy, favoring gentle, incremental interventions such as ultra-low-dose LDN, very low-dose ketotifen, chromolyn sodium, methylene blue, and nutritional ketosis. He cautioned that aggressive dosing often leads to symptom flares and that symptom-chasing can obscure underlying drivers. Dr. Kim shared that two family members had MCAS and that achieving remission took approximately ten years. Dr. Kim also reviewed the mechanism of action of LDN, emphasizing that its effects extend beyond opioid receptor modulation. He highlighted Toll-Like Receptor 4 (TLR4) on microglia as a key target, explaining that microglial activation contributes to neuroinflammation and systemic immune dysregulation. By inhibiting microglial activation, LDN exerts anti-inflammatory effects with a relatively favorable side-effect profile. He summarized his primary reasons for using LDN as brain protection, reduction of neuroinflammation, and lowering systemic inflammation. Common side effects and troubleshooting strategies were addressed. Insomnia was noted as increasingly common in post-COVID patients, with morning dosing suggested. Fatigue may improve with evening dosing. Headaches may respond to mid-day dosing or dose reduction and re-initiation. Diarrhea was described as an expected prokinetic effect, which may be beneficial in patients with SIBO. Mood changes were discussed as potentially related to transient endorphin blockade or neurotransmitter interactions. Filler sensitivities were highlighted, with olive oil suspensions suggested for highly reactive patients. In cases of no perceived effect, cautious dose escalation in coordination with the prescribing clinician was recommended. Additional topics included the synergistic anti-inflammatory effects of combining LDN with a ketogenic diet, with Dr. Kim sharing personal improvement in an autoimmune skin condition. He discussed LDN use in neurological conditions such as dementia, post-stroke recovery, post-concussive syndrome, and traumatic brain injury, often in conjunction with acupuncture neurology. He advised stopping LDN approximately one week before surgery and coordinating with anesthesia. Regarding long-term use, he recommended continuing LDN for up to five years after remission, emphasizing that immune conditions are described as being “in remission” rather than cured. He clarified that naltrexone is FDA-approved, while LDN represents standard off-label use. The session concluded with reference to his SHINE framework: Sleep, Hormones, Infections, Nutrition, and autoimmunE.